Penserra Capital Management LLC Boosts Position in Illumina, Inc. (ILMN)
Penserra Capital Management LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 884 shares of the life sciences company’s stock after buying an additional 102 shares during the period. Penserra Capital Management LLC’s holdings in Illumina were worth $153,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. First Citizens Bank & Trust Co. boosted its stake in Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock worth $536,000 after buying an additional 12 shares in the last quarter. Patten Group Inc. boosted its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the period. Puzo Michael J boosted its stake in shares of Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after buying an additional 25 shares during the period. Eqis Capital Management Inc. boosted its stake in shares of Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock worth $1,200,000 after buying an additional 38 shares during the period. Finally, Broderick Brian C boosted its stake in shares of Illumina by 0.3% in the second quarter. Broderick Brian C now owns 13,152 shares of the life sciences company’s stock worth $2,282,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 93.32% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at 195.94 on Wednesday. The company has a market cap of $28.61 billion, a price-to-earnings ratio of 39.31 and a beta of 0.83. The firm has a 50 day moving average price of $183.92 and a 200-day moving average price of $176.00. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The business had revenue of $662 million for the quarter, compared to the consensus estimate of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 EPS. Equities research analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/30/penserra-capital-management-llc-boosts-position-in-illumina-inc-ilmn.html.
A number of analysts have weighed in on the company. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price target on the stock in a research report on Tuesday, May 23rd. Morgan Stanley reiterated an “underweight” rating and issued a $115.00 price target (up from $108.00) on shares of Illumina in a research report on Monday, May 15th. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target on the stock in a research report on Wednesday, August 2nd. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a research report on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $177.01.
In other Illumina news, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $184.75, for a total value of $26,788.75. Following the completion of the transaction, the senior vice president now owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Omead Ostadan sold 1,672 shares of the firm’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $172.73, for a total transaction of $288,804.56. Following the completion of the transaction, the executive vice president now directly owns 26,242 shares of the company’s stock, valued at approximately $4,532,780.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 138,185 shares of company stock worth $25,063,480. Insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.